{
    "2019-10-30": [
        [
            {
                "time": "2023-10-01",
                "original_text": "Novartis Dips As The World's Most Costly Drug Faces Safety Concerns",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Dips",
                        "World's Most Costly Drug",
                        "Safety Concerns"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "Biogen’s Alzheimer’s Drug Could Be a Winner. One Analyst Recommends the Bet.",
                "features": {
                    "keywords": [
                        "Biogen",
                        "Alzheimer’s Drug",
                        "Winner",
                        "Analyst Recommends"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "Novartis Stock Is Falling After the FDA Puts a Partial Hold on a Gene-Therapy Trial",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Stock Falling",
                        "FDA",
                        "Partial Hold",
                        "Gene-Therapy Trial"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "The Daily Biotech Pulse: Novartis Program Placed On Partial Clinical Hold, Adcom Snub For Amag, Amgen Earnings",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Program",
                        "Partial Clinical Hold",
                        "Adcom Snub",
                        "Amag",
                        "Amgen Earnings"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "Novartis' Zolgensma study halted by FDA amid safety questions",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Zolgensma",
                        "Study Halted",
                        "FDA",
                        "Safety Questions"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}